Literature DB >> 30325426

Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis.

Bharath Ambale-Venkatesh1, Chia-Ying Liu1, Yuan-Chang Liu2, Sirisha Donekal2, Yoshiaki Ohyama2, Ravi K Sharma2, Colin O Wu3, Wendy S Post4, Gregory W Hundley5, David A Bluemke6, João A C Lima2.   

Abstract

Aims: We used contrast-enhanced cardiac magnetic resonance (CMR) to evaluate differences in myocardial fibrosis measured at the year-10 examination between participants with and without cardiovascular (CV) events accrued in a large population based study over the preceding 10-year follow-up period in this retrospective study. Methods and results: The MESA study enrolled 6814 participants free of CV disease at baseline (2000-2002). We included MESA participants who underwent contrast-enhanced CMR at the MESA year-10 exam (N = 1840). We defined a composite CV endpoint of coronary heart disease, heart failure, atrial fibrillation, stroke, and peripheral artery disease. Using CMR, we characterized myocardial fibrosis with late-gadolinium enhancement for scar and T1 mapping indices of diffuse fibrosis. Demographic and CV-risk adjusted logistic (presence of scar) and linear regression (pre-contrast T1, T1 at 12 and 25 min post-contrast, and extracellular volume fraction or ECV) models were used to assess the relationship between fibrosis and events. The mean values of T1 indices were-pre-contrast T1: 977 ± 45 ms; T1 at 12': 456 ± 40 ms; T1 at 25': 519 ± 41 ms; ECV: 27.1 ± 3.2%. One-hundred and forty-six (7.9%) participants had myocardial scar. The presence of scar was strongly associated with prior CV events (adjusted coeff: 1.36, P < 0.001). Lower post-contrast T1 times and higher ECV, indicative of greater diffuse fibrosis were strongly associated with CV events (T1 at 12': coeff = -10.0 ms, P = 0.004; T1 at 25': coeff =-9.2 ms, P = 0.008; ECV: coeff = 1.31%, P < 0.001).
Conclusion: Individuals who suffered prior CV events have greater likelihood of diffuse myocardial fibrosis when compared with event-free individuals living in the same community.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30325426      PMCID: PMC6343084          DOI: 10.1093/ehjci/jey140

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  44 in total

1.  Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease.

Authors:  Raymond Y Kwong; Anna K Chan; Kenneth A Brown; Carmen W Chan; H Glenn Reynolds; Sui Tsang; Roger B Davis
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

Review 2.  Cardiac MRI: a central prognostic tool in myocardial fibrosis.

Authors:  Bharath Ambale-Venkatesh; João A C Lima
Journal:  Nat Rev Cardiol       Date:  2014-10-28       Impact factor: 32.419

Review 3.  Myocardial fibrosis: functional significance and regulatory factors.

Authors:  K T Weber; C G Brilla; J S Janicki
Journal:  Cardiovasc Res       Date:  1993-03       Impact factor: 10.787

4.  Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion.

Authors:  William Chan; Stephen J Duffy; David A White; Xiao-Ming Gao; Xiao-Jun Du; Andris H Ellims; Anthony M Dart; Andrew J Taylor
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

5.  Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model.

Authors:  Luciano C Amado; Bernhard L Gerber; Sandeep N Gupta; Dan W Rettmann; Gilberto Szarf; Robert Schock; Khurram Nasir; Dara L Kraitchman; João A C Lima
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

6.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

Review 7.  Ischaemic and non-ischaemic cardiomyopathies--cardiac MRI appearances with delayed enhancement.

Authors:  E Jackson; N Bellenger; M Seddon; S Harden; C Peebles
Journal:  Clin Radiol       Date:  2007-02-26       Impact factor: 2.350

8.  Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission.

Authors:  Timothy C Wong; Kayla M Piehler; Ian A Kang; Ajay Kadakkal; Peter Kellman; David S Schwartzman; Suresh R Mulukutla; Marc A Simon; Sanjeev G Shroff; Lewis H Kuller; Erik B Schelbert
Journal:  Eur Heart J       Date:  2013-06-11       Impact factor: 29.983

Review 9.  The pathogenesis of cardiac fibrosis.

Authors:  Ping Kong; Panagiota Christia; Nikolaos G Frangogiannis
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

10.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy.

Authors:  Valentina O Puntmann; Tobias Voigt; Zhong Chen; Manuel Mayr; Rashed Karim; Kawal Rhode; Ana Pastor; Gerald Carr-White; Reza Razavi; Tobias Schaeffter; Eike Nagel
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14
View more
  14 in total

Review 1.  Cardiovascular ultrashort echo time to map fibrosis-promises and challenges.

Authors:  Joanne D Schuijf; Bharath Ambale-Venkatesh; Yoshimori Kassai; Yoko Kato; Larry Kasuboski; Hideki Ota; Shelton D Caruthers; João Ac Lima
Journal:  Br J Radiol       Date:  2019-08-08       Impact factor: 3.039

2.  Myocardial fibrosis by T1 mapping magnetic resonance imaging predicts incident cardiovascular events and all-cause mortality: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Mateus D Marques; Raquel Weinberg; Shrey Kapoor; Mohammad R Ostovaneh; Yoko Kato; Chia Ying Liu; Steven Shea; Robyn L McClelland; Wendy S Post; David A Bluemke; João A C Lima; Bharath Ambale-Venkatesh
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-09-10       Impact factor: 9.130

3.  The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway.

Authors:  Tu Wang; Xiaoxu Sun; Haipeng Cui; Kai Liu; Juan Zhao
Journal:  Mol Med Rep       Date:  2020-01-13       Impact factor: 2.952

4.  The impact of tissue-tracking strain on the left atrial dysfunction in the patients with left ventricular dysfunction.

Authors:  Hideki Koike; Satoru Kishi; Naoki Hosoda; Shuhei Takemoto; Daijiro Tomii; Kai Ninomiya; Tetsu Tanaka; Masahiko Asami; Kazuyuki Yahagi; Kota Komiyama; Jun Tanaka; Hitomi Yuzawa; Rine Nakanishi; Tadashi Fujino; Jiro Aoki; Bharath A Venkatesh; João A C Lima; Kengo Tanabe; Takanori Ikeda
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-05

Review 5.  Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives.

Authors:  Yannis Dimitroglou; Constantina Aggeli; Alexandra Alexopoulou; Sophie Mavrogeni; Dimitris Tousoulis
Journal:  J Clin Med       Date:  2019-12-03       Impact factor: 4.241

6.  Matrix metalloproteinase 3 regulates angiotensin II‑induced myocardial fibrosis cell viability, migration and apoptosis.

Authors:  Jin Shu; Yiwen Gu; Li Jin; Haiya Wang
Journal:  Mol Med Rep       Date:  2020-12-20       Impact factor: 2.952

7.  Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction.

Authors:  Anastasia Osokina; Viktoria Karetnikova; Olga Polikutina; Anna Ivanova; Olga Gruzdeva; Yulia Dyleva; Aleksandr Kokov; Natalia Brel; Tamara Pecherina; Olga Barbarash
Journal:  Aging (Albany NY)       Date:  2021-01-11       Impact factor: 5.682

8.  Myocardial Fibrosis Among Antiretroviral Therapy-Treated Persons With Human Immunodeficiency Virus in South Africa.

Authors:  Scott R Shuldiner; Lye-Yeng Wong; Tess E Peterson; Julian Wolfson; S Jermy; H Saad; Mbalabu A J Lumbamba; A Singh; M Shey; G Meintjes; N Ntusi; M Ntsekhe; J V Baker
Journal:  Open Forum Infect Dis       Date:  2020-12-07       Impact factor: 3.835

9.  Human immunodeficiency viral infection and differences in interstitial ventricular fibrosis and left atrial size.

Authors:  Katherine C Wu; Sabina A Haberlen; Michael W Plankey; Frank J Palella; Damani A Piggott; Gregory D Kirk; Joseph B Margolick; Wendy S Post
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-07-20       Impact factor: 6.875

Review 10.  Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis.

Authors:  Denisa Baci; Annalisa Bosi; Luca Parisi; Giuseppe Buono; Lorenzo Mortara; Giuseppe Ambrosio; Antonino Bruno
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.